Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro - Dituri, Francesco; Scialpi, Rosanna; Schmidt, Tannin A.; Frusciante, Martina; Mancarella, Serena; Lupo, Luigi Giovanni; Villa, Erica; Giannelli, Gianluigi (Cell death & disease, 2020)
Keywords: 13/1; 13/106; 13/109; 13/31; 13/51; 13/95; 38/109; 38/77; 631/67/1059/602; 692/308/2778; Antibodies; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biochemistry; Biomedical and Life Sciences; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; CD44 antigen; Cell adhesion & migration; Cell Biology; Cell Culture; Cell migration; Cell proliferation; Extracellular matrix; Fibroblasts; Hepatocellular carcinoma; Humans; Immunology; Inhibitor drugs; Life Sciences; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; mRNA; Phenylurea Compounds - pharmacology; Phenylurea Compounds - therapeutic use; Proteoglycans; Proteoglycans - pharmacology; Proteoglycans - therapeutic use; Pyridines - pharmacology; Pyridines - therapeutic use; Sorafenib - pharmacology; Sorafenib - therapeutic use; Targeted cancer therapy; Transforming growth factor-b; Tumor Microenvironment